AlphaMedix

AlphaMedix is a clinical-stage biotechnology company focused on the development of targeted alpha-emitter radiopharmaceuticals for the treatment of cancer. The company's lead candidate, 212Pb-DOTAMTATE (AlphaMedix), is a somatostatin receptor-targeted therapy that utilizes the alpha-emitter Lead-212 to treat patients with somatostatin receptor-positive neuroendocrine tumors (NETs). By delivering high-energy alpha particles directly to tumor cells, AlphaMedix aims to provide a more effective treatment option with fewer side effects than traditional beta-emitting radiopharmaceuticals. The program has demonstrated significant clinical efficacy and has been granted Breakthrough Therapy Designation by the FDA for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).